RESUMEN
Objective To explore the expression of BCSG 1 in the triple negative breast cancer and the non-triple-negative breast cancer and its significance .Methods The clinical data from 170 patients were retrospectively analyzed,which including 160 breast cancer and 10 benign breast disease .We checked the expression of BCSG 1 in the specimens by the immunohistochemistry to analysis the similarities and differences the BCSG 1 between the triple negative breast cancer and the non-triple negative breast cancer .Results The expression rate of the BCSG 1 was 41.0%in the non-triple negative breast cancer , which was lower than 57.5% in the triple negative breast cancer (χ2 =4.2,P=0.04).Conclusion The expression rate of the BCSG1 in the triple-negative breast cancer is higher than that in the non-triple-negative breast cancer.and it was statistically significant (P<0.05),so the expression of BCSG1 in triple negative breast cancer is unique .It prompt that BCSG1 can be a new treatment target in the triple negative breast cancer .